RT Journal Article
SR Electronic
T1 Advancing Targeted Radionuclide Therapy Through the National Cancer Institute’s Small Business Innovation Research Pathway
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 41
OP 49
DO 10.2967/jnumed.118.214684
VO 60
IS 1
A1 Kaveh Zakeri
A1 Deepa Narayanan
A1 Greg Evans
A1 Pataje Prasanna
A1 Jeffrey C. Buchsbaum
A1 Bhadrasain Vikram
A1 Jacek Capala
YR 2019
UL http://jnm.snmjournals.org/content/60/1/41.abstract
AB The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs of the National Cancer Institute (NCI) are congressionally mandated set-aside programs that provide research funding to for-profit small businesses for the development of innovative technologies and treatments that serve the public good. These two programs have an annual budget of $159 million (in 2017) and serve as the NCI’s main engine of innovation for developing and commercializing cancer technologies. In collaboration with the NCI’s Radiation Research Program, the NCI SBIR Development Center published in 2015–2017 three separate requests for proposals from small businesses for the development of systemic targeted radionuclide therapy (TRT) technologies to treat cancer. TRT combines a cytotoxic radioactive isotope with a molecularly targeted agent to produce an anticancer therapy capable of treating local or systemic disease. This article summarizes the NCI SBIR funding solicitations for the development of TRTs and the research proposals funded through them.